Jackie Iversen, RPh, MS

Recent FDA findings highlight that a major ingredient in popular cold fighters, phenylephrine, may not offer genuine relief.

Diagnostic technologies are advancing quickly, which may lead to therapeutics for age-related diseases to safely reduce chronic low-grade inflammation generated by the immune system.

The FDA considers alcohol hangover as a disease, requiring treatments to be registered as drugs.

As pharmacists, it’s important to understand and embrace the science and the tools that COVID-19 has brought.

As we learn more about inflammatory syndromes, we may get better at using laboratory tests to identify and isolate the actual cellular and chemical processes that drive them.

New research may offer pharmacists a better means of helping customers manage the symptoms of an alcohol hangover.

Amidst the frenzy of blockbuster medicines, the connection between the high price of a drug and how well it works is becoming looser.

Is big pharma overlooking the Goldilocks solutions right under our nose?

Millions of people are still getting COVID-19, so the need for additional tools to fight the virus remains strong.

Ending the COVID-19 pandemic requires an understanding of how to manage the inflammatory dysfunction that the virus causes.